Neumora Therapeutics, Inc. Common Stock earnings per share and revenue
On 06. Nov. 2025, NMRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 5.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an increase of 3.13% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Neumora Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 5.99%, and revenue of $0.00, 0% as expectations.
How did the market react to Neumora Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.53%, changed from $2.62 before the earnings release to $2.58 the day after.
When is Neumora Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 27. Apr. 2026.
What are the forecasts for Neumora Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.